Page 498 - fbkCardioDiabetes_2017

vv

474 Cardio Vascular Safety of Antidiabetic
Drugs Do We Know Enough?

Cardiovascular events.
3.Sulfonylurea use is associated with an increased
risk of adverse cardiovascular events. However, this
risk varies among individual drugs with lowest risk
with gliclazide.

4.TZD especially Roziglitozone increase the risk of
Heart failure, Myocardial infarction and stroke.
5.Saxagliptin and Alogliptin may increase the risk of
heart failure especially in patient with pre-existing
heart failure or renal impairment.

6.Empagliflozin and Liraglutide reduced composite
outcomes for myocardial infarction, stroke and CVD
in populations in which most, if not all, patients had
established atherosclerotic cardiovascular disease.
References:

1. Pawlyk AC, Giacomini KM, Mckean C, Shuldiner AR, Florez JC. Metformin
pharmaco genomics: Current status and future directions diabetes 2014 :
63 : 2590- 2599.
2. Simpson SH, Lee J, Choi S, Vandermeer B, Abdalmonein AS, Featherstone
TR. Mortality risk among sulfonyl ureas: a systematic review and network
metananlysis . Lancet Diabetes Endocrinol 2015 : 3: 43-51.
3. Nissen SE, Wolski K, 2007. Effect of Rosiglitozone on the risk of Myo-
cardial infarction And Death from Cardiovascular causes. N Eng J Med
356 : 2457 – 2471.
4. Scirica BM, bhatt DC, Braunwald E, et al, 2013 Saxagliptin and cardio-
vascular outcomes in patients with type 2 Diabetes Mellitus. N Eng J
Med 369: 1317 -1326.
5. Green JB Bethel MA, Armstrong Pw, et al, 2015 Effects of Sitagliptin on
cardiovascular outcomes in Type 2 Diabetes. N Eng J Med 373: 232- 42.
6. Monami M, Dicembrini I , Nardini C, Fiordelli I, Manucci E, 2014 Effects
of GLP -1 RA on cardiovascular risk : a metaanalysis of randomised clinical
trials. Diabetes obes metab 16 : 38 -47.
7. Zinman B, Wanner C, Lachin JM, et al, 2015 Empagliflozin, cardiovascular
outcomes and mortality in type 2 Diabetes. N Eng J Med 373 : 2117
– 2128.
8. Siraj ES, Rubin DJ, Riddle MC, Miller ME ,et al, 2015 insulin dose and
cardiovascular mortality in the ACCORD trial. Diabetes care 38: 2000-
2008
9. Raz I, Wilson PW, Strojek K, et al. 2009 Effects of Prandial vs Fasting
Glycemia on cardio vascular outcomes in Type 2 Diabetes : the HEART
2D trial. Diabetes care 32: 381-386.vw

GCDC 2017